KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Deferred Taxes (2016 - 2019)

Arbutus Biopharma's Deferred Taxes history spans 4 years, with the latest figure at -$4.3 million for Q3 2018.

  • For Q3 2018, Deferred Taxes changed N/A year-over-year to -$4.3 million; the TTM value through Dec 2020 reached -$28.6 million, changed 0.0%, while the annual FY2019 figure was -$12.7 million, 195.68% down from the prior year.
  • Deferred Taxes for Q3 2018 was -$4.3 million at Arbutus Biopharma, up from -$24.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at -$989000.0 in Q4 2015 and bottomed at -$64.9 million in Q2 2016.
  • The 4-year median for Deferred Taxes is -$19.8 million (2015), against an average of -$25.0 million.
  • The largest annual shift saw Deferred Taxes tumbled 3964.41% in 2016 before it surged 39.5% in 2017.
  • A 4-year view of Deferred Taxes shows it stood at -$989000.0 in 2015, then crashed by 3964.41% to -$40.2 million in 2016, then soared by 39.5% to -$24.3 million in 2017, then soared by 82.39% to -$4.3 million in 2018.
  • Per Business Quant, the three most recent readings for ABUS's Deferred Taxes are -$4.3 million (Q3 2018), -$24.3 million (Q4 2017), and -$40.2 million (Q4 2016).